BPC-I57

BPC-I57 has been examined for its impact on angiogenesis, collagen synthesis, and modulation of the nitric oxide (NO) system. It has also been shown to affect inflammatory mediators such as cytokines and free radicals.

When analyzed in the laboratory setting, BPC-I57 can be used to explore potential synergistic influences on cellular behavior, angiogenesis, and inflammatory pathways.

• The BPC-I57 research kit is intended for laboratory research use only. Researchers may investigate the following potential areas of interest in experimental settings:

• Cellular Behavior in Wound Models. BPC-I57 has been studied for its effects on cell migration, angiogenesis, and collagen production in laboratory models of wound healing.
• Tissue Regeneration Research. BPC-I57 may support investigations into tissue repair and regeneration, particularly in tendons, ligaments, and skin.
• Inflammatory Response Modulation. Studies have explored BPC-I57’s potential to influence inflammatory cytokines and promote anti-inflammatory effects in experimental systems.
• Neuroscience Research. BPC-I57 has been researched for its possible role in nerve healing and protection of neuronal tissue in preclinical models.
• Vascular Studies. Research has examined BPC-I57’s effect on blood vessel formation and vascular integrity, including in models of ischemia and injury.

This BPC-I57 Research Spray Kit is intended solely for laboratory use. It may be employed in structured research settings to study peptide stability, molecular interactions, and delivery mechanisms. The included spray component provides an alternative format for evaluating administration pathways and comparing availability across methods. The peptide is supplied as a lyophilized, water-soluble powder that must be reconstituted before use. Standard laboratory practices apply, including sterile preparation, controlled storage, and proper disposal in accordance with safety guidelines.

1. Vukojevic, Katarina et al. “Stable gastric pentadecapeptide BPC I57 and wound healing.” Frontiers in pharmacology vol. 12 718147
2. Gwyer, Danielle et al. “Gastric pentadecapeptide body protection compound BPC I57 and its role in accelerating musculoskeletal soft tissue healing.” Cell and tissue research vol. 383,3 (2021)
3. Kalogjera, Livije et al. “Stable Gastric Pentadecapeptide BPC I57 in the Therapy of the Nasal Mucosa, Periodontium, and Dry Eye Syndrome.” Biomedicines vol. 10,12 3281. 7 Dec. 2022
4. Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC I57: Theoretical and Practical Implications.” Current neuropharmacology vol. 17,11 (2019)
5. Knezevic, Maro et al. “Stable Gastric Pentadecapeptide BPC I57 Therapy for Periodontitis in Rats.” Biomedicines vol. 10,4 859. 6 Apr. 2022
6. Kokot, Antonio et al. “Stable Gastric Pentadecapeptide BPC I57 Therapy for Primary Abdominal Compartment Syndrome in Rats.” Frontiers in pharmacology vol. 13 861711. 18 Feb. 2022
7. Knezevic, Maro et al. “Stable Gastric Pentadecapeptide BPC I57 and Periodontal Healing in Rats.” Biomedicines vol. 10,2 265. 25 Jan. 2022
8. Sever, Marko et al. “Stable Gastric Pentadecapeptide BPC I57 Therapy for Periodontitis in Rats.” Biomedicines vol. 9,7 774. 29 Jun. 2021
9. Sikiric, Predrag et al. “Stable Gastric Pentadecapeptide BPC I57-NO-system Relation.” Current pharmaceutical design vol. 26,25 (2020)
10. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC I57 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011 Mar;110(3):774-80. doi: 10.1152/japplphysiol.00945.2010. Epub 2010 Oct 28. PMID: 21030672